Subcutaneous occipital nerve region stimulation is becoming an important part of the overall treatment regimen for a number of chronic headache syndromes refractory to nonsurgical, medical management. A combination of improved device technology and methodology, further understanding about appropriate indications and achievement of on-label FDA status should support continued use and success of this neuromodulation modality.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1159/000323034 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!